Increased expression of osteopontin is associated with long-term bee venom immunotherapy

Satoshi Konno, David B.K. Golden, John Schroeder, Robert G. Hamilton, Lawrence M. Lichtenstein, Shau Ku Huang

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: Venom allergen immunotherapy (VIT) is proven to be highly effective for insect allergy, but the mechanisms and the biomarkers associated with clinical efficacy remain elusive. Objective: The aim of this study was to identify candidate biomarkers associated with successful VIT. Methods: Gene chip array and clustering analyses of PBMCs from subjects with or without VIT were performed. Results: From gene chip array and clustering analyses, an increased expression of osteopontin was found in patients who completed 5 to 6 years of VIT and discontinued therapy for 3 to 6 years (completed treatment group) compared with the untreated group. A significantly higher level of serum osteopontin was found in the completed treatment group compared with the untreated group (n = 16 in each group; P <. 001). Conclusion: The upregulation of osteopontin after VIT suggests a role of osteopontin as a candidate biomarker for VIT.

Original languageEnglish
Pages (from-to)1063-1067
Number of pages5
JournalJournal of Allergy and Clinical Immunology
Volume115
Issue number5
DOIs
Publication statusPublished - Jan 1 2005
Externally publishedYes

Fingerprint

Bee Venoms
Immunologic Desensitization
Osteopontin
Venoms
Immunotherapy
Biomarkers
Oligonucleotide Array Sequence Analysis
Cluster Analysis
Insects
Hypersensitivity
Up-Regulation
Therapeutics
Serum

Keywords

  • Biomarker
  • Clustering
  • Gene chip microarray
  • Osteopontin
  • Venom immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Increased expression of osteopontin is associated with long-term bee venom immunotherapy. / Konno, Satoshi; Golden, David B.K.; Schroeder, John; Hamilton, Robert G.; Lichtenstein, Lawrence M.; Huang, Shau Ku.

In: Journal of Allergy and Clinical Immunology, Vol. 115, No. 5, 01.01.2005, p. 1063-1067.

Research output: Contribution to journalArticle

Konno, Satoshi ; Golden, David B.K. ; Schroeder, John ; Hamilton, Robert G. ; Lichtenstein, Lawrence M. ; Huang, Shau Ku. / Increased expression of osteopontin is associated with long-term bee venom immunotherapy. In: Journal of Allergy and Clinical Immunology. 2005 ; Vol. 115, No. 5. pp. 1063-1067.
@article{368bc03b8bac44f3b4cc7bc583847e28,
title = "Increased expression of osteopontin is associated with long-term bee venom immunotherapy",
abstract = "Background: Venom allergen immunotherapy (VIT) is proven to be highly effective for insect allergy, but the mechanisms and the biomarkers associated with clinical efficacy remain elusive. Objective: The aim of this study was to identify candidate biomarkers associated with successful VIT. Methods: Gene chip array and clustering analyses of PBMCs from subjects with or without VIT were performed. Results: From gene chip array and clustering analyses, an increased expression of osteopontin was found in patients who completed 5 to 6 years of VIT and discontinued therapy for 3 to 6 years (completed treatment group) compared with the untreated group. A significantly higher level of serum osteopontin was found in the completed treatment group compared with the untreated group (n = 16 in each group; P <. 001). Conclusion: The upregulation of osteopontin after VIT suggests a role of osteopontin as a candidate biomarker for VIT.",
keywords = "Biomarker, Clustering, Gene chip microarray, Osteopontin, Venom immunotherapy",
author = "Satoshi Konno and Golden, {David B.K.} and John Schroeder and Hamilton, {Robert G.} and Lichtenstein, {Lawrence M.} and Huang, {Shau Ku}",
year = "2005",
month = "1",
day = "1",
doi = "10.1016/j.jaci.2005.01.055",
language = "English",
volume = "115",
pages = "1063--1067",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Increased expression of osteopontin is associated with long-term bee venom immunotherapy

AU - Konno, Satoshi

AU - Golden, David B.K.

AU - Schroeder, John

AU - Hamilton, Robert G.

AU - Lichtenstein, Lawrence M.

AU - Huang, Shau Ku

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Background: Venom allergen immunotherapy (VIT) is proven to be highly effective for insect allergy, but the mechanisms and the biomarkers associated with clinical efficacy remain elusive. Objective: The aim of this study was to identify candidate biomarkers associated with successful VIT. Methods: Gene chip array and clustering analyses of PBMCs from subjects with or without VIT were performed. Results: From gene chip array and clustering analyses, an increased expression of osteopontin was found in patients who completed 5 to 6 years of VIT and discontinued therapy for 3 to 6 years (completed treatment group) compared with the untreated group. A significantly higher level of serum osteopontin was found in the completed treatment group compared with the untreated group (n = 16 in each group; P <. 001). Conclusion: The upregulation of osteopontin after VIT suggests a role of osteopontin as a candidate biomarker for VIT.

AB - Background: Venom allergen immunotherapy (VIT) is proven to be highly effective for insect allergy, but the mechanisms and the biomarkers associated with clinical efficacy remain elusive. Objective: The aim of this study was to identify candidate biomarkers associated with successful VIT. Methods: Gene chip array and clustering analyses of PBMCs from subjects with or without VIT were performed. Results: From gene chip array and clustering analyses, an increased expression of osteopontin was found in patients who completed 5 to 6 years of VIT and discontinued therapy for 3 to 6 years (completed treatment group) compared with the untreated group. A significantly higher level of serum osteopontin was found in the completed treatment group compared with the untreated group (n = 16 in each group; P <. 001). Conclusion: The upregulation of osteopontin after VIT suggests a role of osteopontin as a candidate biomarker for VIT.

KW - Biomarker

KW - Clustering

KW - Gene chip microarray

KW - Osteopontin

KW - Venom immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=18144389419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18144389419&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2005.01.055

DO - 10.1016/j.jaci.2005.01.055

M3 - Article

VL - 115

SP - 1063

EP - 1067

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 5

ER -